POEMS Syndrome: 5 Key Signs, Diagnosis And Treatment
Rare plasma cell disorder causing polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and distinctive skin changes.
Author: Reviewed by Dr. Amanda Oakley, Dermatologist
Synonyms: Crow-Fukase syndrome, Takatsuki syndrome
What is POEMS syndrome?
POEMS syndrome is a rare paraneoplastic syndrome caused by a plasma cell dyscrasia, typically associated with a solitary bone lesion or polyostotic sclerotic bone lesions. It is characterized by polyneuropathy, organomegaly, endocrinopathy, a monoclonal plasma cell proliferative disorder, and skin changes. The acronym POEMS reflects these five core features, though additional symptoms such as edema, effusions, and thrombocytosis are common. POEMS syndrome is distinct from multiple myeloma despite shared plasma cell origins, as it features prominent neurological and dermatological manifestations.
The syndrome arises from overproduction of pro-inflammatory cytokines including vascular endothelial growth factor (VEGF), interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), which drive multisystem involvement. Elevated VEGF levels correlate with disease severity and response to therapy. Incidence is estimated at less than 0.3 cases per 100,000 people annually, affecting adults aged 40–60 years equally across genders and ethnicities.
Who gets POEMS syndrome?
POEMS syndrome predominantly affects individuals in their fifth or sixth decade of life, with a mean age at diagnosis of around 50 years. It occurs worldwide without racial predilection, though early reports noted higher frequency in Japanese populations; subsequent cases have been documented in Europeans, Africans, Hispanics, and Asians. Men and women are equally impacted. Risk factors include underlying plasma cell neoplasms such as osteosclerotic myeloma or Castleman disease. Familial cases are not reported, emphasizing its sporadic nature tied to acquired plasma cell clonality.
What causes POEMS syndrome?
The precise etiology remains unclear, but POEMS syndrome stems from clonal plasma cell proliferation producing a monoclonal immunoglobulin, most commonly λ light chain-restricted. This triggers systemic cytokine dysregulation, particularly VEGF overproduction, leading to vascular permeability, neuropathy, and organomegaly. Bone marrow plasma cells in POEMS express high VEGF, contrasting with low levels in multiple myeloma. Associations with Castleman disease (angiofollicular lymph node hyperplasia) occur in up to 15% of cases, suggesting lymphoproliferative contributions. Genetic mutations are not consistently identified, distinguishing it from hereditary neuropathies.
What are the clinical features of POEMS syndrome?
- Polyneuropathy: A demyelinating sensorimotor peripheral neuropathy affects nearly 100% of patients, starting distally in the lower limbs and progressing proximally. Symptoms include symmetric weakness, paresthesia, pain, and areflexia. Severe cases lead to wheelchair dependence.
- Organomegaly: Hepatomegaly (50–80%), splenomegaly (30–50%), and lymphadenopathy are frequent, detectable by palpation or imaging.
- Endocrinopathy: Present in 70–80%, including hypothyroidism (40–60%), diabetes mellitus (15–30%), hypogonadism, adrenal insufficiency, and growth hormone excess. Edema accompanies hormonal shifts.
- Monoclonal gammopathy: Required for diagnosis, found in bone marrow or serum (IgG or IgA λ chains predominant). Sclerotic bone lesions occur in 95%, often lytic-sclerotic mixed.
- Skin changes: Affect 50–90%; hyperpigmentation (diffuse or sun-exposed areas), hemangiomas (24–44%), hypertrichosis (25–80%), plethora, acrocyanosis, scleroderma-like thickening (25–80%), and leukonychia.
Additional features: Papilloedema (40–70%), pleural/pericardial effusions, ascites, thrombocytosis, fatigue, weight loss, and respiratory compromise from neuropathy or effusions.
Skin findings in detail
Hyperpigmentation, resembling Addison disease, involves increased melanin without melanocyte hyperplasia, affecting extensor surfaces, neck, axillae, and trunk in 50–90%. Multiple angiomas (cherry, lobular capillary, or glomerular hemangiomas) emerge as erythematous papules on trunk and proximal limbs. Hypertrichosis manifests as coarse lanugo-like hair on face, limbs, and chest. Sclerodermiform thickening results from dermal collagen deposition driven by VEGF. Other: plethora, acrocyanosis, hyperhidrosis, vasculitis, calciphylaxis (rare).
How is POEMS syndrome diagnosed?
Diagnosis requires both mandatory criteria (polyneuropathy and monoclonal plasma cell disorder) plus one major and one minor criterion per international consensus.
| Category | Criteria |
|---|---|
| Mandatory | Polyneuropathy; Monoclonal plasma cell proliferative disorder (λ predominant) |
| Major (≥1) | Sclerotic bone lesions; Castleman disease; Elevated VEGF |
| Minor (≥1) | Organomegaly; Extravascular volume overload (edema, effusions); Endocrinopathy; Skin changes; Papilloedema; Thrombocytosis/polycythemia |
Investigations: Nerve conduction studies (demyelination), serum/urine immunofixation, bone marrow biopsy (<5–10% plasma cells), skeletal survey/CT/PET for osteosclerotic lesions, VEGF levels, hormone assays, echocardiography, liver ultrasound.
How is POEMS syndrome treated?
Treatment targets the plasma cell clone; no standardized protocols due to rarity. Options include:
- Radiation therapy: For solitary bone lesions (first-line, response in 50–70%).
- Chemotherapy: Melphalan-dexamethasone, bortezomib, lenalidomide (response 60–80%).
- Autologous stem cell transplant (ASCT): Preferred for eligible patients; 5-year survival >70%.
- Targeted therapies: Daratumumab (anti-CD38), siltuximab (anti-IL-6); emerging VEGF inhibitors.
- Symptomatic: IVIG/plasmapheresis for neuropathy, diuretics for edema, hormone replacement.
75% achieve partial/complete response; monitor VEGF and M-protein. Median survival 10–15 years post-diagnosis, improved with early intervention.
What is the prognosis for POEMS syndrome?
Untreated, POEMS syndrome progresses rapidly to death from respiratory failure or infection (median survival 1–3 years). Modern therapies yield 5-year survival of 60–80%, with ASCT offering best outcomes. Neuropathy improves slowly; persistent deficits common. Relapse managed with re-induction.
Frequently Asked Questions (FAQs)
Q: Is POEMS syndrome curable?
A: No cure exists, but treatments targeting plasma cells induce long-term remission in many, with survival exceeding 10 years.
Q: What does POEMS stand for?
A: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes.
Q: Are skin changes always present in POEMS?
A: No, but occur in 50–90%; hyperpigmentation and hemangiomas are hallmark dermatological signs.
Q: How is POEMS different from multiple myeloma?
A: POEMS features demyelinating neuropathy, sclerotic lesions, and VEGF elevation, unlike lytic lesions and anemia-dominant myeloma.
Q: Can POEMS syndrome be prevented?
A: No known prevention; early detection via neuropathy evaluation improves outcomes.
References
- Cutaneous Manifestations in POEMS Syndrome: Case Report and Literature Review — Dispenza F, et al. 2015-05-15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4448059/
- POEMS syndrome — DermNet NZ. 2023-01-01. https://dermnetnz.org/topics/poems-syndrome
- POEMS syndrome – Symptoms and causes — Mayo Clinic. 2024-06-12. https://www.mayoclinic.org/diseases-conditions/poems-syndrome/symptoms-causes/syc-20352678
- POEMS syndrome: diagnosis, treatments, and outcomes — American Society of Hematology. 2025-01-01. https://ashpublications.org/hematology/article/2025/1/393/556842/POEMS-syndrome-diagnosis-treatments-and-outcomes
- Update on the Diagnosis and Treatment of POEMS Syndrome — JAMA Oncology. 2022-01-01. https://jamanetwork.com/journals/jamaoncology/fullarticle/2780474
Similar Articles
Read full bio of Sneha Tete
